Less COPD Exacerbation Risks for Tiotropium Plus Olodaterol

August 11, 2020


Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

Autopsies, Biopsies Link Lung Injuries to E-Cigarette Use 

August 07, 2020


A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

Older, Male Asthmatics at Greater COVID-19 Severity Risk

August 05, 2020


New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

FDA Approves COPD Triple Therapy

July 24, 2020


The approval are based on a pair of recent phase 3 trials showing the safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate.

Polygenic Risk Score Could Better Predict Severe COPD Risk

July 09, 2020


Genomics, in combination with patient demographic risks, could help better inform clinicians of persons at risk for worsened chronic pulmonary burden.

Expanding the ETHOS Data

June 29, 2020


Where do investigators go next with the 8000-plus COPD patient research?

Individualizing COPD Care

June 25, 2020


In an era of triple therapy combinations, what might a tailored approach look like?

Budesonide Plus LAMA/LABA Significantly Reduces Annual COPD Exacerbation

June 24, 2020


New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

EVALI Hospitalization Stay Linked to Readmission Risk

May 22, 2020


New findings from ATS show the residual effects of vaping-associated lung distress.

Tiotropium/Olodaterol Reduces COPD Adverse Outcomes, Risks

May 21, 2020


A discussion with a study author on promising new findings for the combination inhaler therapy.